Drug Trial Radar · NCT00708162
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
Last checked: Nov 20, 2026Latest source record: May 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
724
Actual
Start
Jul 2008
Primary completion
Dec 2010
Study completion Apr 2015
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Jul 2, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the safety, tolerability and efficacy of a regimen containing once-daily elvitegravir (EVG) versus twice-daily raltegravir (RAL) added to a background regimen (1 fully-active ritonavir (RTV)-boosted protease inhibitor (PI) plus 1 or 2 additional antiretroviral (ARV) agents) in HIV-1 infected, ARV treatment-experienced adults who have documented resistance, or at least six months experience prior to screening with two or more different classes of ARV agents. Participants will be randomized in a 1:1 ratio to receive EVG plus background regimen (Elvitegravir group), or raltegravir plus background regimen (Raltegravir group). Due to known drug interactions, participants in the Elvitegravir group receiving RTV-boosted atazanavir (ATV) or RTV-boosted lopinavir (LPV) as part of their background regimen will receive elvitegravir at a lower dose (85 mg).
Conditions
- HIV Infection
Interventions
ElvitegravirDrug
Elvitegravir (EVG) tablet administered orally once daily with food
RaltegravirDrug
Raltegravir tablet administered orally twice daily according to prescribing information
EVG placeboDrug
Placebo to match elvitegravir administered orally once daily
RAL placeboDrug
RAL placebo administered orally twice daily.
Background regimenDrug
Background Regimen (administered according to prescribing information) contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either ATV, darunavir, fosamprenavir, LPV (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA < 50 Copies/mL at Week 48Time frame: Week 48
Locations
180 sites in 14 countries. Site status is shown where the registry gives one.
Southwest Center for HIV/AIDS
Phoenix, Arizona
Health for Life Clinic, PLLC
Little Rock, Arkansas
Pacific Oaks Medical Group
Beverly Hills, California
AIDS Healthcare Foundation-Research Center
Beverly Hills, California
Center for Special Immunology
Fountain Valley, California
The Living Hope Foundation
Long Beach, California
Kaiser Permanente
Los Angeles, California
Jeffrey Goodman Special Care Clinic
Los Angeles, California
University of Southern California, AIDS Clinical Trials Unit
Los Angeles, California
Peter J. Ruane, MD, Inc.
Los Angeles, California
Tony Mills, MD Internal Medicine
Los Angeles, California
Orange Coast Medical Group
Newport Beach, California
Alameda County Medical Center
Oakland, California
East Bay AIDS Center
Oakland, California
Kaiser Permanente
Sacramento, California
David J. Shamblaw, MD Inc.
San Diego, California
Metropolis Medical
San Francisco, California
San Francisco VA Medical Center/UCSF
San Francisco, California
Connecticut Health Care Group
Glastonbury, Connecticut
Circle Medical LLC
Norwalk, Connecticut
The Stamford Hospital - Stamford ID
Stamford, Connecticut
Whitman-Walker Clinic
Washington D.C., District of Columbia
The George Washington University Medical Center
Washington D.C., District of Columbia
South Florida Clinical Research
Atlantis, Florida
Lifeway , Inc.
Fort Lauderdale, Florida
NorthPoint Medical
Fort Lauderdale, Florida
Therafirst Medical Centers
Fort Lauderdale, Florida
Broward Health CCC
Fort Lauderdale, Florida
Gary Richmond, MD, PA, Inc.
Fort Lauderdale, Florida
Associates In Infectious Diseases
Ft. Pierce, Florida
The Kinder Medical Group
Miami, Florida
University of Miami
Miami, Florida
Wohlfeiler, Piperato and Associates, LLC
North Miami Beach, Florida
Orlando Immunology Center
Orlando, Florida
Infectious Disease of Central Florida
Orlando, Florida
Barry M. Rodwick, M. D.
Safety Harbor, Florida
St. Joseph's Comprehensive Research Institute
Tampa, Florida
Treasure Coast Infectious Disease Consultants
Vero Beach, Florida
AIDS Research Consortium of Atlanta
Atlanta, Georgia
The Emory Clinic, Inc., Division of Infectious Diseases
Atlanta, Georgia
Showing 40 of 180 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.